The Deal
Saturday, November 21, 
3:53 pm

Entries tagged "Bristol-Myers Squibb"

Bristol-Myers looking to swallow Elan in pieces

Rumors of Bristol-Myers Squibb interest in the auction of Irish biotech Elan sent shares up in London trading.


Is Bristol-Myers the next pharma target?

So three megamergers in healthcare, and Bristol-Myers Squibb, which has been rumored to be a takeover target since last summer, is still standing alone.


Here comes pharma's 'me-too' mergers

The pharmaceutical industry is notorious for creating copycat drugs. Now Pfizer's $68 billion bid for Wyeth could prompt Merck, Sanofi-Aventis and other peers to launch 'me-too' mergers.


Bristol-Myers could make ImClone a hard pill to swallow

So Carl Icahn wasn't bluffing. Eli Lilly and Co. is apparently the mystery bidder for ImClone Systems Inc., and the company is in talks to acquire the New York-based biotech company for $6.1 billion, according to a report by The Wall Street Journal. ...


Rabble Babble: ImClone's mystery bidder to reveal itself this week

ImClone Systems Inc. said a mystery bidder, which has tentatively offered a bid of $70 a share or $6.1 billion, has informed the company that it will either make a formal bid or withdraw from talks by the end of the day on Wednesday.  ...


Will someone swallow Bristol-Myers?

Could Bristol-Myers Squibb Co. be entertaining a sale in the future? Sanford C. Bernstein & Co. LLC analyst Tim Anderson might answer "good chance" based on a note he recently wrote, according to a Reuters article. ...



Top tags

You have executed a tag search on Dealscape. On the left,you will find a comprehensive list of stories tagged "Bristol-Myers Squibb." Below are the most-popular tags for Dealscape. On the right of the page you will find a search box to dig deeper into our content.
The Deal Pipeline

Deal Video


Inside The Deal: Avaya Inc.'s Mohamad Ali on the company's next target.


More video...

Crisis On Wall Street
Technology
Deals of The Decade

Community

Industry Insight

Managing your shareholder base

Growth companies and their PE sponsors should be wary of the pitfalls that arise when they layer on tiers of preferred stock.


Industry Insight

Easing the stress of distressed M&A

Corporate buyers face numerous complexities when trying to identify the right moment to purchase a distressed asset.


Editor's Note

Editor's letter: Nov. 16, 2009

Beneath the veneer of Wall Streeters beats the same heart, stirred by the same determinants of behavior.



©Copyright 2008, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.